The majority of the investigation methods of biochemical, morphological and metabolic disorders in hepatic insufficiency and encephalopathy occurrence are inadequate in use in clinical conditions because their invasiveness frequently creates dangerous situations to the patient life and health. That's why, to characterize the mechanisms, constituting the hepatic and cerebral damages base, for testing of a new medicinal preparations, aprobation of a new theoretical and clinical hypotheses, the models of an acute and chronic hepatic insufficiency are applied on the animals, permitting to unify the age, genetic peculiarities and physiological parameters of the individuals involved in experiments, the pathology character, its severity and longevity. Homogeneity of these indexes permits to estimate molecular, structural and functional disorders, laying in the base of pathological process. We have analyzed the experimental models of hepatic insufficiency, basing on the hepatotoxins usage--acetaminophen (paracetamol), carbon tetrachloride, thioacetamide, D-galactosamine, concanavalin A, lipopolysaccharides. Every existing pharmacological model of hepatic insufficiency and encephalopathy for animals owes its own advantages and faults. The choice of a model depends on tasks of the investigation and of the animal species, involved in the procedures.
Download full-text PDF |
Source |
---|
Metab Brain Dis
January 2025
Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus N, Denmark.
Background & Aims: Hepatic encephalopathy (HE), one of the most serious prognostic factors for mortality in alcohol-related cirrhosis (ALD cirrhosis), is not recorded in Danish healthcare registries. However, treatment of HE with lactulose, the universal first-line treatment, can be identified through data on filled prescriptions. This study aimed to investigate if lactulose can be used as a surrogate marker of HE.
View Article and Find Full Text PDFMetab Brain Dis
January 2025
Institute of Liver and Biliary Sciences, New Delhi, India.
Hepatic encephalopathy (HE) is traditionally associated with hepatic parenchymal diseases, such as acute liver failure and cirrhosis. Its prevalence in non-cirrhotic portal hypertension (NCPH) patients, extrahepatic portal vein obstruction (EHPVO), and non-cirrhotic portal fibrosis (NCPF) is less well described. HE in NCPH allows one to study the effect of portosystemic shunting and ammonia without significant hepatic parenchymal injury.
View Article and Find Full Text PDFIntroduction: Chronic liver disease, a progressive deterioration of liver function, has become a significant health problem in the United States. According to the National Vital Statistics Report 2017 from the Center for Disease Control and Prevention, approximately 4.5 million adults have been diagnosed with chronic liver disease and cirrhosis (end-stage liver disease), which is 1.
View Article and Find Full Text PDFNan Fang Yi Ke Da Xue Xue Bao
January 2025
Department of Traditional Chinese Medicine Liver Diseases, Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China.
Objectives: To explore the correlation of serum tryptophan level with 90-day mortality risk in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF).
Methods: This retrospective study was conducted among 108 patients with HBV-ACLF, whose survival outcomes within 90 days after diagnosis were recorded. The correlation of baseline serum tryptophan levels measured by high-performance liquid chromatography with 90-day mortality of the patients was analyzed, and the predictive value of serum tryptophan for 90-day mortality was explored.
Metab Brain Dis
January 2025
Fundación de Investigación Hospital Clínico Universitario de Valencia-INCLIVA, Valencia, 46010, Spain.
Ammonia is a product of amino acid metabolism that accumulates in the blood of patients with liver cirrhosis, leading to neurotoxic effects and hepatic encephalopathy (HE). HE manifestations can range from mild, subclinical disturbances in cognition, or minimal HE (mHE) to gross disorientation and coma, a condition referred to as overt HE. Many blood-based biomarkers reflecting these neurotoxic effects of ammonia and liver disease can be measured in the blood allowing the development of new biomarkers to diagnose cirrhosis patients at risk of developing HE.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!